Table 1 Peptide information.

From: Synthetic angiotensin II peptide derivatives confer protection against cerebral and severe non-cerebral malaria in murine models

Peptide

Sequence

HPLC puritya (%)

Molecular weight (MW)

Obtained molecular weight (m + H+)b

Ang II

DRVYIHPF

98

1045.6

1046

Ang II-SS

CDRVYIHPFC

98

1247.6

1248

VIPF

VIPF

99

474.6

475

  1. Sequences, purity, molecular weight, and mass spectrometry data of peptides used in this study.
  2. aThe HPLC profiles were obtained under the following conditions: Column: Supelcosil C18 (4.6 × 150 mm), 60 Å, 5 μm; Solvent system: A: 0.1% TFA/H2O and B: 0.1% TFA in 60% ACN/H2O; gradient: 5–95% solvent B in 30 min; flow: 1.0 mL min−1; λ = 220 nm; injection volume: 50 µL and sample concentration: 1.0 mg mL−1.
  3. bThe LC/ESI–MS profiles were obtained under the following conditions: Column: Phenomenex Gemini C18 (2.0 × 150 mm),110 Å, 3.0 μm; Solvent system: A: 0.1% TFA/H2O and B: 0.1% TFA in 90% ACN/H2O; Gradient: 5–95% of B in 20 min; Flow: 0.2 mL min−1; λ = 220 nm; Injection volume: 20 μL; Sample concentration: 1.0 mg mL−1 and Mass range: 100–2,500 Daltons.
  4. The bold sequence (Ang II-SS) is to indicate that all residues of the sequence are part of the disulfide bridge formed between the two cysteine residues at each terminus of the peptide.
Back to article page